Effect of livergol on the improvement of fatty liver in patients with cancer undergoing irinotecan- and oxaliplatin-based chemotherapy regimen
BACKGROUND: The aim of this study was to determine the effect of Livergol on the improvement of fatty liver in patients with cancer undergoing irinotecan- and oxaliplatin-based chemotherapy regimen.
MATERIALS AND METHODS: This was an add-on nonrandomized clinical trial study on thirty selected eligible cancer patients undergoing irinotecan (8 patients) and oxaliplatin (22 patients) with diagnosed fatty liver disease-based liver ultrasonography, as well as alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Patients in each group received Livergol at a dose of 140 mg daily for 1 month. ALT and AST levels as well as grade of fatty liver were evaluated before and after intervention.
RESULTS: In the oxaliplatin/Livergol group, 40% and 44.4% of patients who were in Grade 2 and 3 before intervention were altered to Grades 1 and 2, respectively (P = 0.005), and in irinotecan/Livergol group, the mentioned percentages were 80% and 66.7% (P = 0.014). The mean levels of ALT and AST enzymes were decreased in both groups after tacking Livergol; however, the observed decreases were not significantly different between groups.
CONCLUSION: It was concluded that the adding of Livergol to oxaliplatin and irinotecan regimens significantly improved the fatty liver of patients and none of them was superior.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences - 23(2018) vom: 19., Seite 111 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Emami, Hamid [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Alanine aminotransferase |
|---|
| Anmerkungen: |
Date Revised 31.03.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.4103/jrms.JRMS_793_17 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM293203091 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM293203091 | ||
| 003 | DE-627 | ||
| 005 | 20231225074816.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4103/jrms.JRMS_793_17 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0977.xml |
| 035 | |a (DE-627)NLM293203091 | ||
| 035 | |a (NLM)30693046 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Emami, Hamid |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effect of livergol on the improvement of fatty liver in patients with cancer undergoing irinotecan- and oxaliplatin-based chemotherapy regimen |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 31.03.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a BACKGROUND: The aim of this study was to determine the effect of Livergol on the improvement of fatty liver in patients with cancer undergoing irinotecan- and oxaliplatin-based chemotherapy regimen | ||
| 520 | |a MATERIALS AND METHODS: This was an add-on nonrandomized clinical trial study on thirty selected eligible cancer patients undergoing irinotecan (8 patients) and oxaliplatin (22 patients) with diagnosed fatty liver disease-based liver ultrasonography, as well as alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Patients in each group received Livergol at a dose of 140 mg daily for 1 month. ALT and AST levels as well as grade of fatty liver were evaluated before and after intervention | ||
| 520 | |a RESULTS: In the oxaliplatin/Livergol group, 40% and 44.4% of patients who were in Grade 2 and 3 before intervention were altered to Grades 1 and 2, respectively (P = 0.005), and in irinotecan/Livergol group, the mentioned percentages were 80% and 66.7% (P = 0.014). The mean levels of ALT and AST enzymes were decreased in both groups after tacking Livergol; however, the observed decreases were not significantly different between groups | ||
| 520 | |a CONCLUSION: It was concluded that the adding of Livergol to oxaliplatin and irinotecan regimens significantly improved the fatty liver of patients and none of them was superior | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Alanine aminotransferase | |
| 650 | 4 | |a aspartate aminotransferase | |
| 650 | 4 | |a chemotherapy | |
| 650 | 4 | |a fatty liver | |
| 650 | 4 | |a livergol | |
| 700 | 1 | |a Shakeri, Ali Asghar |e verfasserin |4 aut | |
| 700 | 1 | |a Akhavan, Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Shahbazi-Gahrouei, Daryoush |e verfasserin |4 aut | |
| 700 | 1 | |a Akbari, Pouya |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences |d 2009 |g 23(2018) vom: 19., Seite 111 |w (DE-627)NLM207054835 |x 1735-1995 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2018 |g day:19 |g pages:111 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4103/jrms.JRMS_793_17 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2018 |b 19 |h 111 | ||